Sponsorship Link
Merck (NYSE: MRK) and sanofi-aventis (NYSE: SNY) terminated plans to combine their animal health businesses, citing increasing complexity of implementing the proposed transaction.
/
Related Articles
Search Senior Housing Facilities
Create a personal senior housing list with our search. Search Nursing Homes to find U.S. News-rated facilities. For other types of senior housing, you can access Seniors for Living's list of thousands of additional facilities.
Enter location
| or |
Selecting housing type
The companies mutually determined that ending their plan is in the best interests of both companies and their respective shareholders.
"The companies are discontinuing their agreement primarily because of the increasing complexity of implementing the proposed transaction, both in terms of the nature and extent of the anticipated divestitures and the length of time necessary for the worldwide regulatory review process," Merck and sanofi-aventis said.
The joint venture announced on March 2010 was to have combined Sanofi's Merial animal health unit, the maker of the Frontline tick fighter, with Merck's Intervet/Schering-Plough business. Merck bought Schering-Plough in November 2009.
Must Read
Between them, Merial and Intervet had $5.5 billion in sales in 2010.
Follow us
Following the termination, both Merial and Intervet/Schering-Plough will continue to operate independently, the companies said.
ADR's of Sanofi closed Monday's trading at $34.00, while shares of Merck ended at $32.39.
